Advance Journal of Pharmaceutical Research & Review
Volume 1, Issue 5, November 2024, PP: 85-91, ISSN No: 3048-491X

Pharmacogenomics: Personalized Medicine for Cancer Treatment and Drug Response Variability of Cardiovascular Drugs.

Srishti Rai
Medical Product Manager at Junet Pharma Pvt. Ltd.
New Delhi, Delhi-110015, India

Abstract: Pharmacogenomics bridges the gap between genomics and pharmacology by personalizing medical therapies to individual genetic profiles. In recent years, the FDA has approved a number of mutation-based anticancer medications for clinical use. This research will study its usage in the treatment of cancer and variations in the response to cardiovascular medication by pointing out problems, successes, and future approaches. The project attempts to explain the mechanisms underlying genetic heterogeneity in drug response, with a view toward developing tailored ways of improving treatment outcomes. Personalized therapy is one of the biggest and most popular topics in medicine today and in the future direction of development. With continuous progress in genome sequencing and high-throughput screening, the research and development methodologies for personalized therapeutic medications have changed very fast.

Keywords: *Pharmacogenomics, Oncology, gene, Cardiovascular, Personalized Medicine.*

I. Introduction

Pharmacogenomics is a modern field of study that combines pharmacology with genomics, aiming to provide medical treatment based on an individual's genetic makeup. This personalized approach not only serves to enhance the effectiveness of drugs but also to minimize adverse effects, marking a radical shift from the conventional "one-size-fits-all" model of medicine. Its impact is especially strong in treating cancer and cardiovascular diseases, for which genetic variability frequently complicates therapeutic outcomes.

Cancer is essentially heterogeneous, and each case has its peculiar genetic mutations and molecular pathways. Pharmacogenomics will also allow the oncologist to tailor treatments based on biomarkers, such as BRCA1/BRCA2 mutations in breast cancer and expression profiles. This personalization can enhance the success of targeted therapies-like tyrosine kinase inhibitors and immunotherapies-while reducing toxicity and improving patient quality of life.

Pharmacogenomics also benefits cardiovascular diseases, which are among the leading causes of morbidity and mortality globally. There is variability in the response of individuals to cardiovascular drugs, including anticoagulants, beta-blockers, and statins, due to genetic differences. This variability depends on variations in genes coding for drug target enzymes such as CYP2C19 and CYP2D6, important in drug metabolism. For example, pharmacogenomic testing can be used to optimize warfarin dosing and minimize risks of bleeding or clotting complications.

Completion of the Human Genome Project, together with advances in genomics, proteomics, imaging technologies, and molecularly targeted drugs, accelerated the development of personalized medicine. This emerging discipline uses diagnostic tests to select treatments that are likely to work best for each patient or to modify molecular mechanisms affecting health. By combining diagnostic information with medical history, patient-specific circumstances, and values, healthcare providers can work with patients to develop targeted treatment and prevention plans (Su et al., 2021).

Relevance and Goals

The following introduction sets the stage for how pharmacogenomics enhances precision medicine in cancer and cardiovascular diseases. By leveraging genomic insights, clinicians can improve therapeutic outcomes, reduce healthcare costs, and empower patients through informed decision-making.Pharmacogenomics applies a knowledge of genetics to pharmacology as a way of offering higher efficacy of therapy and with lower side effects, considering a number of individual genetic variations. It has had quite great impacts on oncology and cardiovascular medicine, in which variability of a treatment response is considered in the first line of all concerns. In oncology, pharmacogenomics permits conducting targeted therapy according to tumor genetics for better outcomes in advanced or resistant malignancies.

In cardiovascular therapy, genetic variants influence drug metabolism and efficacy, such as statins and beta-blockers, leading to individual variability. Despite these advances, difficulties like cost, accessibility, and ethical concerns impede the

wide application of this approach. The following study reviews the literature; meanwhile, it provides new ways to overcome these limitations and discusses possible opportunities regarding the integration of clinical pharmacogenomics.

II. Literature Review

Pharmacogenomics has become an important tool in tailoring medical treatments to individual genetic profiles, especially in cancer therapy and the management of cardiovascular disease. Research has consistently underlined how genetic variations influence drug efficacy, safety, and variability in patient responses. This section discusses key studies that have underlined the application of pharmacogenomics in these fields.

Precision medicine has increasingly utilized genetic data in cancer therapies, where treatment decisions are pegged on that basis. Pharmacogenomics helps pick those drugs that increase effectiveness yet have minimal toxicities on individual patients. Oncology remains highly recognized as the most advanced area in integrating pharmacogenomics and personalized medicine.

Personalized oncology therapies generally include receptor tyrosine kinase inhibitors, small molecule inhibitors, vaccines, monoclonal antibodies, and antibody-drug conjugates. In addition to developing new targeted therapies, drug repositioning is an increasingly important strategy in personalized oncology. This process mainly involves the identification and tagging of "complementary diagnostic" biomarkers for existing drugs that enhance their effectiveness in certain genetic contexts.

1. Target Therapy in Oncology

Sotiriou and Pusztai: Genetic changes, such as mutations in the genes EGFR in lung cancer and HER2 in breast cancer, have been major factors in the choice of targeted therapy and have helped in drastically reducing toxicities while improving patient outcomes. Targeted therapies, for example, tyrosine kinase inhibitors, revolutionized cancer treatment by addressing the molecular drivers at the core of the disease.

Such a principle can be exemplified from specific targeted treatments: for instance, the NSCLC subjects presenting with EGFR gene alterations exhibit superior response rates for EGFR inhibitors, as is seen with erlotinib and gefitinib therapy. Correspondingly, another cancer genetic disorder, the presence of CML related to BCR-ABL gene aberration, was found highly responsive against imatinib, a potent tyrosine kinase inhibitor,. These are all possible through pharmacogenomic testing, which enables the clinician to apply appropriate targeted therapies, hence increasing efficacy while minimizing side effects and providing a better management strategy in cancer.

Regarding the medicine for lung cancer ramucirumab, for example, the FDA suggests using the drug only on patients with mutations of EGFR and ALK. The effectiveness of the treatments can, therefore, fall in line more with the genetic profile of the patient. In this respect, the repurposing of drugs has also become popular since it saves a great deal of time, reduces overall costs, reduces the safety hazards arising out of it, and accelerates approvals relating to drugs.

These repurposed drugs are now being used in cancers, neuropsychiatric diseases, infections, cardiovascular and metabolic disorders. Reused drugs could be made use of for reuse in a variety of manners in the arenas of cancer, neuropsychiatric diseases, infections, cardiovascular diseases, and metabolic disorders. Big Data analytics further facilitates personalized medicine wherein precision medicine can be treated on a highly personalized approach tailored according to genes, life style, and environmental or other factors. This holistic approach represents a significant advancement in tailoring medical care to the unique needs of each patient.

2. Pharmacogenomics of Cancer and Chemotherapy

According to Zhao et al. (2020), genetic polymorphisms in the metabolizing enzymes, such as CYP2D6 and CYP3A4, greatly affect the metabolic activity of drugs such as tamoxifen and docetaxel, respectively, and constitute one important aspect of pharmacogenomics. The therapeutic efficacy and toxicity of several chemotherapeutic agents such as 5-fluorouracil and irinotecan depend profound on genetic backgrounds. For example, mutations in the DPYD gene, encoding the enzyme DPD, result in severe toxicity under 5-FU treatment. In another example, variants of the UGT1A1 gene affect the metabolism of irinotecan and thus its drug-induced toxicity. In general, genomic screening of such variants will enable personalized chemotherapy so that adverse effects can be minimized, improving therapeutic outcomes, hence possibly revolutionizing the care of cancers.

3. Immunotherapy and Genetic Markers

Sun et al. (2018) emphasized that polymorphism in genes such as PD-L1, CTLA-4, and HLA generates a difference in efficacy of checkpoint inhibitors. Most cancer treatments have been revolutionized by immunotherapy and some diseases like melanoma or lung cancer. Biomarkers that include PD-L1 expression and tumor mutational burden have been strongly related to responses from immune checkpoint inhibitors like pembrolizumab, among others, as reported in a study by Garon et al.

(2015). By applying pharmacogenomic testing, clinicians are able to highlight those patients who probably get the most benefit from immunotherapy, moving the field onward in providing personalized care.

In total, until 2018, FDA approved 355 pharmacogenomic biomarkers and 284 drugs. By their nature, pharmacogenomic biomarkers usually include genetic variants-that is, gene tags or abnormally expressed proteins (Najjar & Allison, 2022). They help in the identification of patients who will benefit or will not benefit from a particular treatment and reduce adverse drug reactions; they even aid in optimizing drug dosage. According to Chang et al. (2020), of these personalized medicines, anti-tumor drugs are a significant portion because of the discovery of oncogenic driver genes and the development of therapies targeting molecular alterations.

Variability in Cardiovascular Drug Response

Cardiovascular diseases are the leading causes of death worldwide. Generally, genetic variations in metabolic enzymes and transporters are the basis for variability in medication response. Pharmacogenomics plays an important role in addressing variability in cardiovascular drug responses and significantly enhances the personalization of treatments for cardiovascular diseases. Yusuf, S., et al. (2020) It is particularly transformative for medications like anticoagulants, statins, and antiplatelet agents, where genetic variations affect metabolism, efficacy, and side effect profiles.

1. Warfarin and CYP2C9 Variants

The therapeutic window of the anticoagulant warfarin is narrow, and its metabolism is influenced by genetic variability. Variants in the CYP2C9 gene encoding cytochrome P450 enzymes significantly alter warfarin metabolism. For example, patients carrying the CYP2C9*2 or CYP2C9*3 alleles require lower doses to achieve therapeutic anticoagulation and avoid bleeding complications. Similarly, genetic variations in CYP2C19 influence the bioactivation of antiplatelet drugs like clopidogrel, which are responsible for variable antiplatelet responses. Such pharmacogenomic testing enables the clinician to adjust warfarin dosing based on the presence of such variants, thereby enhancing its safety and effectiveness.

2. Statins and Variants in SLCO1B1

Statins represent a widely prescribed class of medications for hyperlipidemia, with associated cardiovascular events. On the other hand, statins induce muscle toxicity in a genetically predisposed individual. The variants in SLCO1B1 encode for a hepatic organic anion transporter that modifies transport and metabolism of statins. Some SLCO1B1 polymorphisms increase the risk for statin-induced myopathy, adverse muscle events, and non-adherence.By identifying these genetic variants through pharmacogenomic testing, health care providers can select appropriate types of statins and proper dosing to minimize the risk of adverse effects while ensuring therapeutic efficacy. Pharmacogenomics, by such advance, makes cardiovascular disease management more precise and safe, epitomizing the potential of personalized medicine.

3. Beta-Blockers and ADRB1 Variants

Pharmacogenomics is enabling personalized cardiovascular therapies based on genetic determinants of drug response and toxicity, such as beta-blockers and aspirin. Beta-blockers are a class of drugs important in the treatment of hypertension and heart failure but show variable efficacy in different individuals, depending on genetic background. Of importance are polymorphisms in the ADRB1 gene encoding the beta-1 adrenergic receptor.

These variations also affect the response to beta-blockers, including metoprolol. For example, some ADRB1 polymorphisms have been implicated in blunted responsiveness to beta-blockers in patients with heart failure, which would likely reduce their therapeutic benefit. Through pharmacogenomic testing, clinicians are able to determine those patients who might not be good responders to specific beta-blockers and make treatment plans that ensure better outcomes.

4. Aspirin and COX-1 Gene Variants

Aspirin is a broadly used antiplatelet agent in cardiovascular protection, which exercises an antiplatelet action via inhibition of COX-1. However, genetic polymorphism of the COX-1 gene may influence the efficacy of aspirin in preventing cardiovascular events. A number of polymorphisms in COX-1 were identified, and several show a modified platelet response to aspirin that might reduce the protective effect in some individuals (Bertrand et al., 2003).The ability to pharmacogenomic-screen these genetic variants allows for aspirin therapy optimization in individual patients toward better cardiovascular outcomes. Incorporation of pharmacogenomic insights will help in the personalization of treatments with beta-blockers and aspirin, with enhanced efficacy and minimized risks in cardiovascular care.

Innovations

A few of these technology advances in personalized medicine through innovations in AI and genomics include the following. AI-Driven Biomarker Discovery: This subject involves the use of Artificial Intelligence in the identification of new biomarkers and interactions between drugs and genes, possibly with targeted therapies. Point-of-Care Genomic Testing: Utilized in the manufacture of low-cost rapid-test genomic kits, it develops personalized approaches for treatment. First pilot studies recorded 30% improvement in time-to-treatment with significant improvement in patient outcomes by about 20%. Dong & Pang (2021) identified that cancer pharmacogenomics are AI models which achieve 85% in predicting responses of patients to the EGFR inhibitors by analyzing their genetic profile. They further identified that 40% of the population reflected a significant association between CYP2C19 polymorphism and resistance to clopidogrel.

III. Proposed Work

This research paper examines the progress of pharmacogenomics, which, to date, has empowered personalized medicine development in the treatment of cancer and monitoring responses of cardiovascular drugs. Material and methods are primarily based on research methodology in the form of a critical literature review. The review of the studies related to pharmacogenomics regarding cancer and the responses of cardiovascular drugs was done through the use of major scientific databases like PubMed, Scopus, and Web of Science.

Data analysis will therefore focus on clinical trials and meta-analyses, with greater emphasis being placed on the critical evaluation of genetic markers and their correlation with patients' outcomes. A comparative assessment will be made in order to analyze how pharmacogenomics influences clinical practice, mainly from an economic point of view and considering accessibility.It will investigate some of the key questions, including the contribution of genetic polymorphisms to the determination of drug efficacy and safety, economic and ethical challenges in the implementation of pharmacogenomics, and how such findings might inform future research and policymaking.

Preliminary knowledge from the literature indicates that pharmacogenomics has greatly improved therapeutic response. In cancer treatments, it reduced drug resistance and toxicity, and in cardiovascular care, genetic profiling has resulted in more precise prescription of drugs, leading to fewer side effects and increased patient compliance. However, economic disparity is still an issue toward global adoption.Pharmacogenomics holds high promise both for individualized cancer treatment and cardiovascular disorders. In all these processes, much would have to be undertaken in considering cost, ethical, and integrative difficulties in healthcare if such advances were to be translated to routine clinical settings. These are issues that would require further collaboration efforts by government, healthcare provisions, and research institutions.

IV. Results and Conclusion

Personalized medicine is based on tailoring medical treatment to a patient's genetic profile, combined with his or her environmental factors and lifestyle. This approach maximizes health outcomes while minimizing ineffective therapies and their potential side effects.Pharmacogenomics has largely taken this concept to a different level by identifying genetic markers guiding targeted therapies. Examples include mutations in the EGFR gene in lungcancer and amplification of HER2 in breast cancer, which have paved the way for the use of drugs such as erlotinib and trastuzumab, respectively (Johnson & Cavallari, 2013). Genetic profiling for the provision of individualized cancer treatment has also been proven to enhance the therapeutic efficacy of the treatment while minimizing toxicities. For example, TPMT genotyping may provide the chance to modify the dosage of thiopurine in patients with specific variations of the TPMT gene, thus decreasing the risk of myelosuppression.

Besides this, pharmacogenomics has also driven the success of immunotherapies such as checkpoint inhibitors-for example, pembrolizumab in PD-L1-positive cancers-further improving outcomes in genetically compatible patients. Genetic polymorphisms in certain enzymes, exemplified by CYP2C19 and CYP2D6, within cardiovascular medicine, result in the described differential patient responses to clopidogrel and beta-blockers. Variants in VKORC1 and CYP2C9 genes influence warfarin metabolism; their application requires personalized dosing strategies in order to achieve effective anticoagulation without bleeding risks.

Similarly, SLCO1B1 polymorphisms have been implicated in statin-induced myopathy, reinforcing the importance of genetic testing in predicting and preventing adverse drug reactions. A disease diagnosis and treatment are swiftly taking on the dimensions of personalized medicine. In this regard, rapidly advancing genomics and drug discovery technologies provide a high degree of credibility for therapies based on an individual's unique characteristics. Currently, combination treatments and natural product-based approaches

have also reached clinical practice to create newer options in cancer care.

Genomic developments give an evident insight into the underlying causes of disease and offer potential to identify individuals for whom a certain therapy might be most effective. This knowledge of pharmacogenomics is crucial because, in the design of individualized therapies, it enables the identification of genetic variations with drug metabolism, efficacy, and toxicity implications. Therefore, this precision allows clinicians to select and dose drugs optimally for the best clinical response with minimal side effects, according to Cecchin & Stocco, 2020.

The major challenges to the clinical implementation include barriers to integrating pharmacogenomics into routine care. There is limited genomic data from diverse populations, too. The high cost of genetic testing and bioinformatics infrastructure adds to clinical implementation. There also exist some ethical concerns related to the privacy of genetic information and discrimination (Sharma & Schilsky, 2021). Novel technologies are improving the analysis of genomic data in the identification of new targets (Ho et al., 2020).

Furthermore, the deeper understanding of disease biology has driven more effective targeted therapies. Pharmacogenomics is becoming an integral part of cardiovascular and oncological care. Its use in cancer involves an ever-expanding armamentarium of genetic-profile-based chemotherapy and targeted therapies to improve efficacy by minimizing toxicity. In this case, cardiovascular medicine continues to exploit knowledge of host genetic factors that modulate the response to drugs such as warfarin, statins, or beta-blockers to optimize use and enhance safety. Success has been more limited in other diseases.

Despite these clinical advances, genetic testing finds only a very limited practice diffusion in the majority of countries. Its wider delivery will require healthcare providers to be educated adequately in interpreting and implementing genetic findings effectively. Personalized therapies, although highly promising, still face challenges. Further research and translation by interdisciplinary collaboration into routine practice are needed to enhance quality of life and therapeutic efficacy for patients. The integration of pharmacogenomics with other emerging technologies has allowed researchers to disclose new insights into disease mechanisms and the development of personalized approaches. Future breakthroughs may involve new drug targets and therapies based on natural products and traditional medicine.

References

[1] Arbel, Y., Abuzeid, W., Rosenson, R. S., Weisman, A., &Farkouh, M. E. (2018). Old drugs for new indications in cardiovascular medicine. Cardiovascular Drugs and Therapy, 32, 223-232.

[2] Bertrand, M., et al. (2003). "Cox-1 gene polymorphisms and aspirin response in cardiovascular disease." Circulation, 107(24), 3023-3028.

[3] Cecchin, E., & Stocco, G. (2020). Pharmacogenomics and personalized medicine. Genes, 11(6), 679.

[4] Chang, C. J., Chen, C. B., Hung, S. I., Ji, C., & Chung, W. H. (2020). Pharmacogenetic testing for prevention of severe cutaneous adverse drug reactions. Frontiers in Pharmacology, 11, 969.

[5] Deenen, M. J., et al. (2011). "Clinical implementation of pharmacogenomics: From DNA to patient." Nature Reviews Drug Discovery, 10(11), 911-920.

[6] Domingos, S., André, V., Quaresma, S., Martins, I. C., Minas da Piedade, M. F., & Duarte, M. T. (2015). New forms of old drugs: improving without changing. Journal of Pharmacy and Pharmacology, 67(6), 830-846.

[7] Dong, H., & Pang, Z. (2021). Pharmacogenomics in cancer precision medicine: Toward patient stratification and therapy optimization. Frontiers in Medicine, 8, 770-779. https://doi.org/10.3389/fmed.2021.770779

[8] Druker, B. J., et al. (2001). "Imatinib as a selective inhibitor of BCR-ABL in the treatment of chronic myeloid leukemia." Blood, 98(3), 907-913.

[9] Garon, E. B., et al. (2015). "Pembrolizumab for the treatment of non-small-cell lung cancer." New England Journal of Medicine, 372(21), 2020-2031.

[10] Ho, D., Quake, S. R., McCabe, E. R., Chng, W. J., Chow, E. K., Ding, X., ... &Zarrinpar, A. (2020). Enabling technologies for personalized and precision medicine. Trends in biotechnology, 38(5), 497-518.

[11] Hopewell, J. C., Parish, S., Offer, A., Link, E., Clarke, R., Lathrop, M., ... & Collins, R. (2018). Impact of genetic variants in SLCO1B1 on statin-induced myopathy in a randomised trial. The Lancet, 380(9841), 951-959. https://doi.org/10.1016/S0140-6736(18)32068-7

[12] Jain, K. K. (2002). Personalized medicine. Current opinion in molecular therapeutics, 4(6), 548-558.

[13] Johnson, J. A., & Cavallari, L. H. (2013). "Pharmacogenetics and cardiovascular disease—implications for personalized medicine." Pharmacological Reviews, 65(3), 987-1009.

[14] Johnson, J. A., & Cavallari, L. H. (2015). Pharmacogenetics and cardiovascular disease—implications for personalized medicine. Nature Reviews Cardiology, 12(2), 116-129. https://doi.org/10.1038/nrcardio.2014.183

[15] Johnson, J. A., et al. (2004). "Beta1-adrenergic receptor gene polymorphisms and heart failure treatment." Pharmacogenetics, 14(2), 89-96.

[16] Letai, A., Bhola, P., &Welm, A. L. (2022). Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer cell, 40(1), 26-35.

[17] Liggett, S. B., Cresci, S., Kelly, R. J., Syed, F., &Kittleson, M. M. (2021). The pharmacogenomics of beta-blockers. Pharmacogenomics Journal, 21(3), 153-162. https://doi.org/10.1038/s41397-021-00222-0

[18] Link, E., et al. (2008). "SLCO1B1 variants and statin-induced myopathy: a genome-wide study." New England Journal of Medicine, 359(8), 789-799.

[19] Litman, T. (2019). Personalized medicine—concepts, technologies, and applications in inflammatory skin diseases. Apmis, 127(5), 386-424.

[20] McDonald, E. S., Clark, A. S., Tchou, J., Zhang, P., & Freedman, G. M. (2016). Clinical diagnosis and management of breast cancer. Journal of Nuclear Medicine, 57(Supplement 1), 9S-16S.

[21] Mikhail, N., et al. (2011). "DPYD gene and 5-fluorouracil toxicity." Pharmacogenomics Journal, 11(3), 163-170.

[22] Najjar, S., & Allison, K. H. (2022). Updates on breast biomarkers. VirchowsArchiv, 480(1), 163-176.

[23] Nakagawa, K., Garon, E. B., Seto, T., Nishio, M., Aix, S. P., Paz-Ares, L., ... &Dakhil, S. (2019). Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 20(12), 1655-1669.

[24] Paez, J. G., et al. (2004). "EGFR mutations in lung cancer." Nature, 304(5676), 1012-1015.

[25] Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., ... &Pirmohamed, M. (2019). Drug repurposing: progress, challenges and recommendations. Nature reviews Drug discovery, 18(1), 41-58.

[26] Ratain, M. J., & Von Hoff, D. D. (2020). "Pharmacogenomics in oncology: Implementation of personalized medicine." The Lancet Oncology, 21(8), e350-e358.

[27] Rieder, M. J., et al. (2005). "CYP2C9 polymorphisms and warfarin dosing." New England Journal of Medicine, 352(22), 2271-2283.

[28] Rivory, L. P., et al. (2002). "UGT1A1 and irinotecan metabolism." Clinical Cancer Research, 8(6), 2012-2020.

[29] Relling, M. V., & Evans, W. E. (2015). "Pharmacogenomics in the clinic." Nature, 526(7573), 343-350. https://doi.org/10.1038/nature15817

[30] Sharma, M. R., & Schilsky, R. L. (2021). Role of pharmacogenomics in precision medicine for cancer. Pharmacological Reviews, 73(1), 147-162. https://doi.org/10.1124/pr.120.019455

[31] Serebruany, V. L., Malinin, A. I., & Ohman, E. M. (2016). The polymorphism of CYP2C19 and its impact on clopidogrel efficacy. Thrombosis Journal, 14(3), 1-7. https://doi.org/10.1186/s12959-016-0083-4

[32] Sotiriou, C., & Pusztai, L. (2015). Gene-expression signatures in breast cancer. New England Journal of Medicine, 360(8), 790-800. https://doi.org/10.1056/NEJMra0801289

[33] Su, M., Zhang, Z., Zhou, L., Han, C., Huang, C., & Nice, E. C. (2021). Proteomics, personalized medicine and cancer. Cancers, 13(11), 2512.

[34] Sun, H., Huang, Q., Huang, M., Wen, H., Deng, L., Wei, Y., & Zhang, G. (2018). Genetic polymorphisms and PD-L1 inhibitors' efficacy in cancer treatment. Cancer Treatment Reviews, 70(1), 120-128. https://doi.org/10.1016/j.ctrv.2018.08.005

[35] Workman, P. (2002). Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone. Cancer detection and prevention, 26(6), 405-410.

[36] Yusuf, S., et al. (2020). Impact of genetic variation on cardiovascular drug response: A systematic review. Journal of Clinical Pharmacology, 60(12), 1689-1701. https://doi.org/10.1002/jcph.1755

[37] Zhao, X., Zhang, Y., Chen, Y., Wang, X., & Wang, X. (2020). Influence of CYP450 polymorphisms on the pharmacokinetics and toxicity of chemotherapy drugs. Frontiers in Pharmacology, 11(102), 1-12. https://doi.org/10.3389/fphar.2020.00102

[38] Zhou, Y., Peng, S., Wang, H., Cai, X., & Wang, Q. (2024). Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products. Genes, 15(4), 468. https://doi.org/10.3390/genes15040468